Physician profile
James Everett Hancock
NPI 1386702066
$5,475.60
in general payments reported to CMS, 2019-2025
19 companies · $609 in 2025
The $609 reported for 2025 was more than what 92% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,190 · 2020: $203 · 2021: $253 · 2022: $704 · 2023: $1,928 · 2024: $588 · 2025: $609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,384 · Travel and Lodging: $742.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,384.24 |
| Travel and Lodging | $741.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,302.78 | 2019-2025 | Wavewriter Alpha Prime 16, General - Pain Management, Na |
| Medtronic, INC. | $1,161.54 | 2022-2025 | Intellis Adaptivestim, Kyphon Express II Kyphopak Tray, Synchromedii |
| Abbott Laboratories | $664.36 | 2019-2025 | Proclaim, Eterna |
| Medtronic USA, INC. | $496.09 | 2019-2020 | |
| Relievant Medsystems, INC. | $206.38 | 2022-2023 | Intracept |
| Collegium Pharmaceutical, INC. | $130.20 | 2019 | |
| Spr Therapeutics, INC | $128.43 | 2022-2025 | Sprint Pns System |
| Pfizer INC. | $87.03 | 2019 | |
| Pacira Therapeutics, INC. | $72.16 | 2019 | |
| Tersera Therapeutics LLC | $47.56 | 2019 | |
| Forte Bio-Pharma LLC | $37.66 | 2019 | |
| Nevro Corp. | $27.70 | 2019 | |
| Stryker Corporation | $26.78 | 2019 | |
| Saol Therapeutics INC. | $21.26 | 2020 | |
| Pacira Pharmaceuticals Incorporated | $19.33 | 2023 | Iovera, Zilretta |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $16.19 | 2019 | |
| Zyla Life Sciences, INC. | $11.85 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.73 | 2019 | |
| Mml US, INC. | $6.57 | 2023 | Reactiv8 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Hancock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.